Immunome, Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Immunome, Inc. (IMNM) reported Adjustments to Additional Paid in Capital, Warrant Issued of $1.34 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-16.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2023-03-16
- Immunome, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Immunome, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-09-30 was $432.00K, a 10700.00% increase year-over-year.
- Immunome, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-06-30 was $801.00K.
- Immunome, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-03-31 was $105.00K.
- Immunome, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2021 was $1.34M, a 81.05% decline from fiscal 2020.
- Immunome, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2020 was $7.06M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $432.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.23M derived: sum of 3 quarters · filed 2023-03-16 | $1.34M 10-K · filed 2023-03-16 |
| 2021-09-30 | $432.00K 10-Q · filed 2022-11-14 | $1.23M derived: sum of 2 quarters · filed 2022-11-14 | $1.34M 10-Q · filed 2022-11-14 | $8.39M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $801.00K 10-Q · filed 2022-08-05 | $906.00K 10-Q · filed 2022-08-05 | $7.96M derived: sum of 3 quarters · filed 2022-08-05 | $7.96M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $105.00K 10-Q · filed 2022-05-12 | $7.16M derived: sum of 2 quarters · filed 2022-05-12 | $7.16M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $7.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $7.06M derived: sum of 2 quarters · filed 2022-03-28 | $7.06M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $4.00K 10-Q · filed 2021-11-15 | $7.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $3.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |